Thanks for bringing this up again Led, it did not get any traction when I brought this up In the early summer. As a holder of both companies I think it would be great to bring them back into a single fold as an epigenetic "powerhouse". From time to time we have talked about the potentially grey area wrt the two companies IP, this problem would obviously be resolved. I agree that the combined company would be a much superior offering from an investment bankers perspective especially with the reduced risk due to multiple trials and compounds and no possibility of cannabalizing each other's markets down the road. I think a valuation of each company could probably be arrived at very fairly. Due to the present ownership in each company Eastern would probably push for the relatively higher value being placed on Zenith while Hepalink would obviously want a relatively higher placed on Resverlogix. As has been mentioned the method of resolving Resverlogix debt would need to be laid out given that Zenith is currently debt free but as part of a combined entity would be tied to that debt.